{"DataElement":{"publicId":"6199761","version":"1","preferredName":"Disease Positron Emission Tomography Metabolic Response Type","preferredDefinition":"Text that describe the evaluation of the metabolic response of disease or disorder by positron emission tomography (PET).","longName":"DZ_PET_MET_RESP_STAT","context":"Theradex","contextVersion":"1","DataElementConcept":{"publicId":"6199769","version":"1","preferredName":"Disease or Disorder Positron Emission Tomography Metabolic Response Assessment","preferredDefinition":"Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function._A technique for measuring the gamma radiation produced by collisions of electrons and positrons (anti-electrons) within living tissue. In positron emission tomography (PET), a subject is given a dose of a positron-emitting radionuclide attached to a metabolically active substance (for example, 2-fluoro-2-deoxy-D-glucose (FDG), which is similar to a naturally occurring sugar, glucose, with the addition of a radioactive fluorine atom). When living tissue containing the positron emitter is bombarded by electrons, gamma radiation produced by collisions of electrons and positrons is detected by a scanner, revealing in fine detail the tissue location of the metabolically-active substance administered._An evaluation of the metabolic response of the disease to the therapy._The final result of a determination of the value, significance, or extent of.","longName":"2404658v1.0:6199767v1.0","context":"Theradex","contextVersion":"1","ObjectClass":{"publicId":"2404658","version":"1","preferredName":"Diseases and Disorders","preferredDefinition":"A definite pathologic process with a characteristic set of signs and symptoms. It may affect the whole body or any of its parts, and its etiology, pathology, and prognosis may be known or unknown.","longName":"C2991","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Disease or Disorder","conceptCode":"C2991","definition":"Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"005AD6E5-0651-6A35-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-09-09","endDate":null,"createdBy":"PWEST","dateCreated":"2005-09-09","modifiedBy":"ONEDATA","dateModified":"2005-09-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"6199767","version":"1","preferredName":"Positron Emission Tomography Metabolic Response Assessment","preferredDefinition":"A technique for measuring the gamma radiation produced by collisions of electrons and positrons (anti-electrons) within living tissue. In positron emission tomography (PET), a subject is given a dose of a positron-emitting radionuclide attached to a metabolically active substance (for example, 2-fluoro-2-deoxy-D-glucose (FDG), which is similar to a naturally occurring sugar, glucose, with the addition of a radioactive fluorine atom). When living tissue containing the positron emitter is bombarded by electrons, gamma radiation produced by collisions of electrons and positrons is detected by a scanner, revealing in fine detail the tissue location of the metabolically-active substance administered.:An evaluation of the metabolic response of the disease to the therapy.:The final result of a determination of the value, significance, or extent of.","longName":"C17007:C123623:C25367","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Positron Emission Tomography","conceptCode":"C17007","definition":"A technique for measuring the gamma radiation produced by collisions of electrons and positrons (anti-electrons) within living tissue. In positron emission tomography (PET), a subject is given a dose of a positron-emitting radionuclide attached to a metabolically active substance (for example, 2-fluoro-2-deoxy-D-glucose (FDG), which is similar to a naturally occurring sugar, glucose, with the addition of a radioactive fluorine atom). When living tissue containing the positron emitter is bombarded by electrons, gamma radiation produced by collisions of electrons and positrons is detected by a scanner, revealing in fine detail the tissue location of the metabolically-active substance administered.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Metabolic Response","conceptCode":"C123623","definition":"An evaluation of the metabolic response of the disease to the therapy.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Assessment","conceptCode":"C25367","definition":"The final result of a determination of the value, significance, or extent of.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"69FCFD06-52C3-158D-E053-F662850A0827","latestVersionIndicator":"Yes","beginDate":"2018-04-16","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-04-16","modifiedBy":"ONEDATA","dateModified":"2018-04-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008550","version":"1","preferredName":"Disease Response","preferredDefinition":"the response criteria (includes RECIST and others) and associated documentation of disease.","longName":"DZ_RESP","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22C0651-216B-5273-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"69FCFD06-52D4-158D-E053-F662850A0827","latestVersionIndicator":"Yes","beginDate":"2018-04-16","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-04-16","modifiedBy":"SOKKERL","dateModified":"2018-04-19","changeDescription":".","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"6199759","version":"1","preferredName":"Positron Emission Tomography Type","preferredDefinition":"A technique for measuring the gamma radiation produced by collisions of electrons and positrons (anti-electrons) within living tissue. In positron emission tomography (PET), a subject is given a dose of a positron-emitting radionuclide attached to a metabolically active substance (for example, 2-fluoro-2-deoxy-D-glucose (FDG), which is similar to a naturally occurring sugar, glucose, with the addition of a radioactive fluorine atom). When living tissue containing the positron emitter is bombarded by electrons, gamma radiation produced by collisions of electrons and positrons is detected by a scanner, revealing in fine detail the tissue location of the metabolically-active substance administered._Something distinguishable as an identifiable class based on common qualities._A condition or state at a particular time._Something distinguishable as an identifiable class based on common qualities.","longName":"6199759v1.0","context":"Theradex","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"40","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Complete metabolic response-CMR","valueDescription":"Tumor Complete Metabolic Response","ValueMeaning":{"publicId":"4359035","version":"1","preferredName":"Tumor Complete Metabolic Response","longName":"4359035","preferredDefinition":"A finding of disappearance of metabolic tumor activity in target and non-target lesions, marked by a decrease in tumor standardized uptake value to the level of surrounding normal tissue.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Tumor Complete Metabolic Response by PET","conceptCode":"C116095","definition":"A finding obtained using FDG-PET imaging demonstrating the disappearance of metabolic tumor activity in target and non-target lesions, marked by a decrease in tumor standardized uptake value to the level of surrounding normal tissue.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FC1F85B2-9DF1-AA07-E040-BB89AD434094","latestVersionIndicator":"Yes","beginDate":"2014-06-18","endDate":null,"createdBy":"PATELV","dateCreated":"2014-06-18","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"69FBE70A-C172-342F-E053-F662850AD321","beginDate":"2018-04-16","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-04-16","modifiedBy":"ONEDATA","dateModified":"2018-04-16","deletedIndicator":"No"},{"value":"No metabolic response - NMR","valueDescription":"No Metabolic Response","ValueMeaning":{"publicId":"6074023","version":"1","preferredName":"No Metabolic Response","longName":"6074023","preferredDefinition":"The non-affirmative response to a question.: An evaluation of the metabolic response of the disease to the therapy.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Metabolic Response","conceptCode":"C123623","definition":"An evaluation of the metabolic response of the disease to the therapy.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6595BD80-B83E-6841-E053-F662850A8CC6","latestVersionIndicator":"Yes","beginDate":"2018-02-19","endDate":null,"createdBy":"MORENOC","dateCreated":"2018-02-19","modifiedBy":"ONEDATA","dateModified":"2018-02-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"69FBE70A-C15B-342F-E053-F662850AD321","beginDate":"2018-04-16","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-04-16","modifiedBy":"ONEDATA","dateModified":"2018-04-16","deletedIndicator":"No"},{"value":"Partial metabolic response","valueDescription":"PMR","ValueMeaning":{"publicId":"2721724","version":"1","preferredName":"PMR","longName":"2721724","preferredDefinition":"A decrease of metabolic tumor activity in all relevant lesions, based on a pre-defined threshold.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Partial Metabolic Response","conceptCode":"C123609","definition":"A decrease of metabolic tumor activity in all relevant lesions, based on a pre-defined threshold.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"43EB8AD7-B6CE-5423-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"CHILLIJ","dateCreated":"2008-01-17","modifiedBy":"COOPERM","dateModified":"2020-12-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"69FBE70A-C188-342F-E053-F662850AD321","beginDate":"2018-04-16","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-04-16","modifiedBy":"ONEDATA","dateModified":"2018-04-16","deletedIndicator":"No"},{"value":"Not Assessed   NA","valueDescription":"NOT ASSESSED","ValueMeaning":{"publicId":"2559594","version":"1","preferredName":"NOT ASSESSED","longName":"2559594","preferredDefinition":"Indicates that an assessment was not performed.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Not Assessed","conceptCode":"C139527","definition":"Indicates that an assessment was not performed.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B5D7-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"MMADDINENI","dateModified":"2024-02-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6BDD9D58-D599-4AA4-E053-F662850AAC5F","beginDate":"2018-05-10","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-05-10","modifiedBy":"ONEDATA","dateModified":"2018-05-10","deletedIndicator":"No"},{"value":"Indeterminate Response   IR","valueDescription":"Indeterminate Response","ValueMeaning":{"publicId":"6272413","version":"1","preferredName":"Indeterminate Response","longName":"6272413","preferredDefinition":"A response that is neither favorable nor unfavorable.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Indeterminate Response","conceptCode":"C123589","definition":"A response that is neither favorable nor unfavorable.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6BDB14F5-C3AF-40C4-E053-F662850AE75B","latestVersionIndicator":"Yes","beginDate":"2018-05-10","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-05-10","modifiedBy":"SOKKERL","dateModified":"2018-10-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6BDD9D58-D5A3-4AA4-E053-F662850AAC5F","beginDate":"2018-05-10","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-05-10","modifiedBy":"ONEDATA","dateModified":"2018-05-10","deletedIndicator":"No"},{"value":"Progressive metabolic disease - PMD","valueDescription":"Progressive Metabolic Disease","ValueMeaning":{"publicId":"6260516","version":"1","preferredName":"Progressive Metabolic Disease","longName":"6260516","preferredDefinition":"An increase of metabolic tumor activity in all relevant lesions, based on pre-defined thresholds, or the development of new lesions.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Progressive Metabolic Disease","conceptCode":"C123608","definition":"An increase of metabolic tumor activity in all relevant lesions, based on pre-defined thresholds, or the development of new lesions.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6B3F48C6-2BB7-271A-E053-F662850ACD44","latestVersionIndicator":"Yes","beginDate":"2018-05-03","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-05-03","modifiedBy":"ONEDATA","dateModified":"2018-05-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6B3F48C6-2BD2-271A-E053-F662850ACD44","beginDate":"2018-05-03","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-05-03","modifiedBy":"ONEDATA","dateModified":"2018-05-03","deletedIndicator":"No"},{"value":"Progressive metabolic response - PMR","valueDescription":"Progressive Metabolic Response","ValueMeaning":{"publicId":"6199760","version":"1","preferredName":"Progressive Metabolic Response","longName":"6199760","preferredDefinition":"Advancing in extent or severity.: An evaluation of the metabolic response of the disease to the therapy.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Progressive","conceptCode":"C25254","definition":"Advancing in extent or severity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Metabolic Response","conceptCode":"C123623","definition":"An evaluation of the metabolic response of the disease to the therapy.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"69FBE70A-C12A-342F-E053-F662850AD321","latestVersionIndicator":"Yes","beginDate":"2018-04-16","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-04-16","modifiedBy":"ONEDATA","dateModified":"2018-04-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6A0E80EF-1852-39EA-E053-F662850A9254","beginDate":"2018-04-16","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-04-17","modifiedBy":"ONEDATA","dateModified":"2018-04-17","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008551","version":"1","preferredName":"Assessments","preferredDefinition":"evaluations of the patient and the patient's disease.","longName":"ASSESS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22DA727-6718-5A2D-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"6199758","version":"1","preferredName":"Positron Emission Tomography Type","preferredDefinition":"A technique for measuring the gamma radiation produced by collisions of electrons and positrons (anti-electrons) within living tissue. In positron emission tomography (PET), a subject is given a dose of a positron-emitting radionuclide attached to a metabolically active substance (for example, 2-fluoro-2-deoxy-D-glucose (FDG), which is similar to a naturally occurring sugar, glucose, with the addition of a radioactive fluorine atom). When living tissue containing the positron emitter is bombarded by electrons, gamma radiation produced by collisions of electrons and positrons is detected by a scanner, revealing in fine detail the tissue location of the metabolically-active substance administered.:Something distinguishable as an identifiable class based on common qualities.","longName":"C17007:C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Positron Emission Tomography","conceptCode":"C17007","definition":"A technique for measuring the gamma radiation produced by collisions of electrons and positrons (anti-electrons) within living tissue. In positron emission tomography (PET), a subject is given a dose of a positron-emitting radionuclide attached to a metabolically active substance (for example, 2-fluoro-2-deoxy-D-glucose (FDG), which is similar to a naturally occurring sugar, glucose, with the addition of a radioactive fluorine atom). When living tissue containing the positron emitter is bombarded by electrons, gamma radiation produced by collisions of electrons and positrons is detected by a scanner, revealing in fine detail the tissue location of the metabolically-active substance administered.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"69FBE70A-C101-342F-E053-F662850AD321","latestVersionIndicator":"Yes","beginDate":"2018-04-16","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-04-16","modifiedBy":"ONEDATA","dateModified":"2018-04-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"69FBE70A-C112-342F-E053-F662850AD321","latestVersionIndicator":"Yes","beginDate":"2018-04-16","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-04-16","modifiedBy":"COOPERM","dateModified":"2020-12-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2008601","version":"1","longName":"C3D Domain","context":"CCR","ClassificationSchemeItems":[{"publicId":"2811685","version":"1","longName":"CCR","context":"CCR"}]},{"publicId":"2182125","version":"1","longName":"CCR Implementation","context":"CCR","ClassificationSchemeItems":[{"publicId":"2811673","version":"1","longName":"C3D","context":"CCR"}]}],"AlternateNames":[{"name":"CCR","type":"USED_BY","context":"CCR"}],"ReferenceDocuments":[{"name":"PET-Based Metabolic Response","type":"Preferred Question Text","description":"PET-Based Metabolic Response Assessment","url":null,"context":"Theradex"}],"origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"69FC2277-BA1B-2DAE-E053-F662850AC025","latestVersionIndicator":"Yes","beginDate":"2018-04-16","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-04-16","modifiedBy":"COOPERM","dateModified":"2020-12-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}